LTAS
VNDA icon

Linden Thomas Advisory Services’s Vanda Pharmaceuticals VNDA Stock Holding History

Linden Thomas Advisory Services’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,722
Closed -$103K – 556
2025
Q4 		$103K Buy
11,722
+67
+0.6% +$369 0.01% 483
2025
Q3 		$58.2K Buy
11,655
+431
+4% +$2K 0.01% 481
2025
Q2 		$53K Buy
11,224
+575
+5% +$2.51K 0.01% 476
2025
Q1 		$48.9K Buy
+10,649
New +$49.6K 0.01% 458

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Linden Thomas Advisory Services's VNDA Position: Q1 2026 in Review

Linden Thomas Advisory Services sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 11,722 shares — an estimated $103K sold.

Linden Thomas Advisory Services first reported a position in VNDA in Q1 2025 and held it in 4 quarters. The position peaked at $103K in Q4 2025. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Linden Thomas Advisory Services reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 11,722 Vanda Pharmaceuticals shares in Q1 2026, an estimated $103K.
  • Linden Thomas Advisory Services first reported a position in Vanda Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Linden Thomas Advisory Services's Vanda Pharmaceuticals position peaked at $103K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q1 2026, filed 10 Apr 2026.